Mad Money w/ Jim Cramer · · Transcript & summary by WhipScribe
Jim Cramer breaks down what NVIDIA's leadership shake-up and the Anthropic IPO mean for investors, plus a rare CEO look at Moderna's cancer vaccine.
Tap a chapter to play it from that moment in the show's own player; the transcript opens there too.
“Remember, the board represents you, not Jensen.” Jim Cramer · at 2:20 — ▶ hear it from here
“The people who are too eager, they get hurt.” Jim Cramer · at 29:15 — ▶ hear it from here
Jim Cramer spends most of this episode on the fallout from NVIDIA's chief executive resigning after an undisclosed affair with a direct report, a relationship five executives confirmed to the New York Times. Cramer says the board had no real choice and that the exit was right for shareholders, even though he admired the executive's record. He argues the stock slid less than expected because the company still holds tens of billions in cash, and that the real risk is sanctions or export problems rather than accounting fraud. He names Colette Kress, the interim chief executive, as the keeper of the numbers, and says he will trim his own position.
The second theme is Anthropic's upcoming IPO, which Cramer says is also why the market held up. He lays out what the financials miss: a large cash pile against heavy compute commitments, most code written by the company's own AI, and open questions about price cuts, new products, regulation and liability. The float is small, about 6% of shares, with 22 staggered lockup releases after the offering. Cramer expects a big first-day pop followed by pressure, as happened with SpaceX, and says he is wary of buying on the first day.
Away from NVIDIA, Kraft Heinz's chief executive explains a turnaround that paused a planned split in favour of $700 million of investment in brands like Heinz and Kraft Mac and Cheese, with growth expected to return in the second half of 2027. Moderna's chief executive then describes a personalized melanoma vaccine developed with Merck, citing a 42% improvement over Keytruda, an FDA filing targeted before year end, and availability for Americans hoped for in 2027.
Jim Cramer said the NVIDIA board answers to shareholders, not to the founder, and that the company wants him kept far away from its operations while investigations run. He argued the stock fell less than it might have because the scandal involves possible liability and sanctions rather than the kind of financial fraud that leaves a company with little cash.
“Remember, the board represents you, not Jensen.”Jim Cramer · 2:20
Jim Cramer said Colette Kress, NVIDIA's chief financial officer, is the interim CEO and the person who has explained the company to him for years. He said she knows how the business works better than the departing chief executive does, and that she is the keeper of the numbers, which lowers the risk of a financial scandal.
“She is tough as nails.”Jim Cramer · 3:48
Jim Cramer said Anthropic had about $132 billion in cash, cash equivalents and short-term investments at the end of September, and that its offering could add roughly $100 billion more. He said that cushion matters because the company faces about $900 billion in compute commitments.
“I've noted that the company had $132 billion in cash, cash equivalents, and short-term investments at the end of September.”Jim Cramer · 23:39
Jim Cramer said Kraft Heinz rang the New York Stock Exchange opening bell after moving its listing from the Nasdaq, and called its investor day a terrific one. He said the company expects sales and operating profits to start growing again in the second half of next year.
“Then it's a terrific investor day.”Jim Cramer · 13:38
Jim Cramer said Moderna was up more than 680% for 2026 after Moderna and Merck reported that their personalized cancer shot helped keep melanoma from returning after surgery. He noted the stock fell 7% on the day of his report, after strong vaccine sales had turned the company to a surprise profit the week before.
“Moderna is now up more than 680% for 2026.”Jim Cramer · 31:11
Jim Cramer argues that NVIDIA's CEO had to resign after an undisclosed affair with a direct report, and that the board had no real choice. He says shareholders are better off with the change, that interim CEO Colette Kress can steady the company, and that the stock's losses should be judged on liability risk rather than on the founder's past record.
Jim Cramer said NVIDIA's chief executive had to resign in disgrace after an undisclosed affair with a direct report, which five executives confirmed to the New York Times. He said the board had no other choice and that the move was right for shareholders, even though he admired the executive's record. Cramer said he was crushed personally, but that it was his job not to be betrayed.
Jim Cramer said Colette Kress, NVIDIA's chief financial officer, is now interim CEO and has been his main contact at the company, running the conference calls and answering his questions. He called her tough and precise and said she knows how the company works better than the departing chief executive does. Cramer said she will be on full display when NVIDIA reports next Tuesday.
Jim Cramer said next week's Anthropic offering represents about 6% of shares outstanding, and that about 7% of shares will float on the first day after a tranche of non-founder employee shares unlocks. The rest unlock gradually through 22 lockup releases, starting less than a month after the IPO. He said that could produce a big first-day pop followed by downward pressure, similar to what happened with SpaceX.
Jim Cramer's pros include about $132 billion in cash and short-term investments at the end of September, with roughly $100 billion more possibly coming from the offering, against about $900 billion in compute commitments. He also said about 90% of code contributions to Anthropic are written by Claude. His cons are regulatory constraints, liability from a cyberattack or from autonomous models acting badly, pressure from price cuts, and the need for new hit products beyond Claude Code.
Kraft Heinz's chief executive, speaking with Jim Cramer on Mad Money, said the company paused a plan to split into two businesses and put $700 million into its brands instead. He said Heinz is growing in the U.S., Brazil and China, that new Kraft Mac and Cheese products have helped, and that growth should return in the second half of 2027. He also said he bought $5 million of company shares shortly after taking the job.
Moderna's chief executive told Jim Cramer the company is working with Merck to file its personalized melanoma cancer vaccine with the FDA before the end of 2026, and hopes to make it available to Americans in 2027 if regulators approve. He said the vaccine showed a 42% improvement over Keytruda in a phase 3 melanoma study, and that the full data set was published in the New England Journal of Medicine.
Jim Cramer said his trust still holds too much NVIDIA stock at around $166 a share, so he plans to sell some once it is no longer restricted from trading. He said investors with large NVIDIA gains should take some profits off the table rather than risk giving them back if the stock falls further.
Our own transcript of the public episode, with a timestamp about every 90 seconds. Tap a timestamp to play the episode from there in the show's own player; the link button on a paragraph copies a link that opens this page there.
0:00At Edward Jones, we believe rich means opening yourself to new possibilities. That's why your dedicated financial advisor meets you where you are, helping you move forward with confidence. Let's find your rich. Edward Jones, member SIPC. There's rewarding, and then there's remarkably rewarding with Chase Sapphire Reserve. Like enjoying access to our award-winning lounges with two complimentary guests every time you travel. Learn more at chase.com slash sapphire reserve. Cards issued by JPMorgan Chase Bank and a member FDIC subject to credit approval terms apply. My mission is simple, to make you money. I'm here to level the playing field for all investors. There's always a bone working somewhere and I promise
0:40to help you find it. Mad Money starts now. Hey, I'm Kramer. Welcome to Mad Money. Welcome to Kramerica. My friends, I'm just trying to make a little bit of money here. My job is not just to entertain, but to do some teaching. So call me at 1-800-743-CNBC. Tweet me at Jim Kramer. In the end, Jensen Wong was more of a liability to the company he founded and ran than a positive. The possibility of him being a mark for a Chinese spy, giving up key secrets or even helping them get the latest chips, having them find their way to the People's Republic, cannot be ruled out. The ill-advised, not very well hiddenhidden affair with one of his direct reports, something five NVIDIA executives confirmed to the New York Times,
1:29is flat out against the rules at most companies and is embarrassingly unprofessional. So his staying on as CEO of NVIDIA just because he was NVIDIA to many and the stock price would be much higher if he weren't removed, simply wasn't an option. This morning, he resigned, and yes, he did resign in disgrace. Did we want him to go? If we are shareholders, pre-disgrace, of course not. He was an amazing CEO. Post-disgrace, knowing what we know now about the way that this brilliant man put the institution he said he loved into jeopardy? I have to say yes. In any case, I don't think the board had any other choice. I'm not a morality coach, nor am I a board member of NVIDIA. I owe a pile of stocks for a living. So on this day where the Dow dipped 189 points,
2:20the S&P fell 0.35%, the Nasdaq dropped 0.39%, we have to figure out what a Jensen-less NVIDIA is worth, clinically. First, let's take something I heard all day off the table. He will not be allowed to participate in NVIDIA's affairs, either in a public or a sidebar fashion. No. Jensen Wong is left to build it. The company wants him as far away as possible because it wants to isolate him and keep the multiple investigations his actions have caused from tainting the day-to-day operations of this company. Remember, the board represents you, not Jensen. It's bad enough that there will be employees investigated to see if they turned a blind eye to what might have been a clear pipeline of high-end NVIDIA chips to the
3:03PRC via his paramour's ties to the Communist Party, there will also be an investigation of the sort of affair Jensen Wong had with Kimberly Powell, NVIDIA's vice president of health care, an important position that might not have been handled as well as it should have because of the relationship. So then you ask, how come the stock didn't go down even more today? First, I remind you that it's been going down for months, and it's not exactly like it's expensive here. The company reports next week, and I believe it will be a huge quarter. Remember, this isn't Sendit or Enron or WorldCom. Horrendous financial scandals where there was little to nothing in the bank. That's the kind of scandal you must run from no matter what. There's tens of billions of dollars in the bank here, no accounting
3:48irregularities. This is scandal involving potential liability from those orders procured by a spy and the sanctions that might be placed on NVIDIA by the government. Some of it is less likely now that Jensen has been cut loose. Second, the person named interim CEO, Colette Kress, who is the current CFO. I know people think I was close to Wong and maintain a good relationship. But let me tell you something. My principal contact at the company had been Colette Kress. She runs the conference call, an amazing conference call. She's the person who explains things to me and answers my questions. Kress knows more about the company than Wong does. Not the technology, but how the company works. She is tough as nails. Yeah, the kinds of nails that come out of a nail gun. To say that she
4:36doesn't suffer fools gladly understates her precision and her rigor and the lack of viewers if you ask something stupid, which I have done and regretted immediately. She will hold things together well in the interim. And with Crest at the helm, the idea that there is a financial scandal of the kind that makes you have to sell the stock goes away because she is the keeper of the numbers. She will be on full display when they report next Tuesday, as she always is on the conference calls. I say bravo. The last reason that the market didn't fall apart today is the upcoming anthropic IPO. We're on the verge of what might be the biggest IPO of all time and the ramifications for the Semi, especially NVIDIA,
5:15and that the ecosystem that Jensen created with all these investments are now going to pay off. They may actually be able to recoup most of those investments once this happens. Now, remember your cross-disciplines here, people. As I told CMEC investing club members today during our morning meeting streaming show at 1020, if you are one of the myriad NVIDIA millionaires, the club and Jensen Wong created, thank you, Jensen, for doing that. You need to be sure you take at least some of those profits off the table. Don't ever turn a successful investment into an unsuccessful trade, no matter who it's with. We don't know what else is going to come out from what will almost certainly be multiple investigations. Whatever it is, I don't think it's going to be any good.
5:55You don't want to give up all of your gains if the stock falls further. It fell further today after many of the analysts jumped ship and downgraded the stock from buy to hold. But I think there could be many more of those ahead. We don't know what NVIDIA's competitors are going to do. We know that AMD has been catching up with its own product lines. Broadcom's quite competitive. Google and Amazon, less so. But Amazon does have what may soon be a $50 billion semiconductor business. That's the second half of 27. Can they catch up to NVIDIA with its clear four-year product roadmap? If you think, as the analysts seem to believe, that the other 42,000 other employees don't matter much, then you're going to get cold feet, even if you see the great numbers next Tuesday.
6:36I can hear the razzing about last good quarter all over the place. We know that the investigations might lead to international export curtailments, which would hurt the business and lead to number cuts. That means that no matter how low the price journey's multiple gets, the stock could still go lower. So where do I come out? We've made, you know, look, we've made fortunes in NVIDIA for the Chabot Trust, but we still have too much with the stock here at 166. That means it cuts to selling some when we are not restricted from doing so. And we've been restricted for ages and ages and had to ride this one down. But here's something you might be happy about. I did a small canvas today of executives who I thought could be the Tim Cook
7:17to Jensen Steve Jobs. Tall order, as Cook was a first ballot Hall of Famer. But the caliber of candidates here who are interested in this job made me feel that there won't be a better NVIDIA, just a different one, one that is better organized, perhaps, and not just throwing money around to wrap up companies in an NVIDIA ecosystem. Maybe we'll get someone who decides it's OK to take profits on the company's successful investments in other companies. Now, the anthropic deal will liquefy the ecosystem that Jensen won't create it. Maybe we'll have a CEO who does more to highlight the company's other 42,000 employees, the ones who I think are insulted by what's happening, the ones that don't wear the leather jackets.
8:01They exist, too. The bottom line, am I mad about Jensen? Yes. I like them so damn bottom line, am I mad about Jensen? Yes. I liked him so damn much. I am crushed by this. I thought he was a better guy. Did he betray me? Nah, no. It's my job to not be betrayed, to be smarter, to have my eyes more wide open. He didn't betray me. Did he betray you, the shareholders? Yeah. End of story. Dennis in Ohio. Dennis. Hey, how are you, Jim? Dennis, I'm okay. How about you? Hey, I woke up today, so it's a good day, right? You know what? I actually said that this morning, so yeah. The answer is yeah to that. Okay. Hey, I'm calling on Sunoco. It's gone from 80 in August down in the low 60s now. Yeah. They're having another record year.
8:47Keep raising their dividends. Low P.E. ratio. I just don't get it. No, I like it. Well, it's going down because people feel the war's over. I remember the day it came public, and I thought, what a great idea. But then I go, I was a son of Philadelphia. I think this thing's a great piece of paper. I think you're in good shape. Just own it. If it goes down to 6%, buy more. Let's go to Robert in New York. Please, Robert. Jim, so nice to hear your voice and how positive you are. And I got to tell you something, you're doing a great job for us. With the ups and downs, you're making us steady and you're basically telling us what to do, which is nibble away at some of the stocks going down. And in the end, it doesn't matter because this has happened 50 times throughout Wall Street where the market has corrected up 10 percent, down 15 percent.
9:33So if you play the Kramer rule, which is how to make money in any market, you can't lose in the end. Thank you, Robert. If you listen to Robert, you can't see right now, but I'm walking down the street right now that I walked down in 1981 when the Dow was at 1,000. And everyone told me it is so ridiculously overvalued. Keep your money in CDs. I didn't know what a CD was, but I knew what a stock was. I crushed it. All right, so go ahead. I'm sorry. That's why you are the top guy on Wall Street. That's why you're here to help. And there's like guys who are billionaires. And all we do is hear from them. And they're fantastic because when you're a billionaire, you're fantastic. Just kidding. You're fantastic because you help the common man.
10:12And that's what I want. That's what Emma wants me to do. That's my daughter. She's great. Your daughter. Phenomenal. But anyway, I like the false. Yeah. Let's make them. Let's make the listeners some money or you tell me if I'm wrong here. Okay. This next company's latest results show a sharp earnings reset with weak appliance demand, inflation, and housing softness, pressuring the sales and the margins. Now, the management is relying on price increases, manufacturing changes, and a $290 million structural savings to support a profitability recovery in 2027. Now, I own this stock. I bought it when the earnings got touted. I met this guy out. He used to work for the company. He goes, this is a good company down the road.
10:54It shouldn't be this cheap. World's full, baby. You know, okay, so listen, I love the product, but maybe they need a kind of a CEO refresh because someone has to pay for that decline. And I think it has to be the CEO. I like the guy very much, but the decline is too much. I thank you for your kind words. If I help the common for the regular person, that's a heck of a lot better than helping all the billionaires I used to help. They were never that appreciative anyway. Anyway, on May Money Tonight, Kraft Heinz gave a very optimistic investor day presentation. It's been ringing today's MISD bell. I'm finding out more about the path for packaged goods with the CEO of Mike's thing is great. Then I'm rounding out my series on Anthropix, hotly anticipated IPO.
11:39But look at some of the more unusual aspects of the deal that you need to know about. And Moderna's promising cancer vaccine has been propelling the stock higher this year. What else is in the pipeline? I'm going to find out with the company's CEO. So stay with Kramer. Don't miss a second of Mad Money. Follow at Jim Kramer on X. Have a question? Tweet Kramer. Hashtag Mad Mentions. Send Jim an email to madmoneyatcnbc.com or give us a call at 1-800-743-CNBC. Miss something? Head to madmoney.cnbc.com. This year's girls' trip to Telluride was the best. We weren't you next time. And that pistachio gelato was too good. So where should we go next year? I've got ideas. Chase Sapphire Preferred. The card that's preferred for a reason.
12:50Cards issued by JPMorgan Chase Bank and a member FDIC. Subject to credit approval. Terms apply. At Edward Jones, we believe rich is more than caring about the latest and greatest. It's also taking care of what gives your life meaning. That's why your dedicated financial advisor meets you where you are with personalized financial strategies that help protect what matters so you can preserve your progress while creating a path forward. The key to being rich is knowing what counts. Let's find your rich together. Edward Jones, member SIPC. This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Schwab Market Update, an original podcast from Charles Schwab,
13:38provides an information-packed daily market preview on stock updates, U.S. and global economic news, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com slash market update podcast, or find Schwab Market Update wherever you get your podcasts. This will be exciting, and it's not about NVIDIA. This morning, Kraft Heinz, the package food giant, rang the opening bell to celebrate the move from the Nasdaq to the New York Stock Exchange. Then it's a terrific investor day. The company said it expects sales and operating profits to start growing again in the second half of next year. She's consistent in accelerating growth by 2029.
14:20Since taking the helm nearly a year ago, CEO Steve Kaelin has invested $700 million into the business, hired 400 new employees. This is so different from the old one. Let's check in with Steve, the CEO of Crab Plants, to find out more about his comeback plan. Steve, I am so glad to see you here. And I just had how much you invest in the company. But let's just get started by how much have you invested yourself? Well, thanks for having me, Jim, as always. So shortly after I started with the company, obviously I'm paid a lot in stock, but I went into the open market and bought $5 million worth of Kraft Hein shares because I like to put my money where my mouth is. I'm the team that I'm going to put together. I know you sure do. I was going through your amazing deck and you
14:59had this line. I think it kind of epitomizes where we are. We always had the right assets to win. Now we are realizing their full potential. Those assets are pretty great, aren't they? They're fantastic. Think about the Heinz brand. I mean, Heinz is loved everywhere around the world, rejected nowhere, right? We've got a huge opportunity to grow Heinz in its home market of the United States, which we've returned it to growth. We've got huge opportunities all around the world. Heinz in Brazil is doing phenomenally well. Heinz in China is opening up whole new occasions with eggs and breakfast. And so Heinz plays everywhere. Heinz Soup has just been introduced in Canada. It's off to a flying start. So Heinz is a phenomenal brand and it really is gold. Now, you are actually reaching
15:44people differently from just traditional advertising. You've embraced the channels that I always think people should start embracing. Meta and TikTok. Yeah, there's no question. Look, today's consumer shows up differently than they did historically. You still have to be in historic, traditional places, but we have to be where the consumer are. We have to we have to go meet the consumer where they are. That's social. that's digital, and the future is it's agentic as well. So we have to continue to evolve our capabilities. We have to invest in our capabilities and we have to meet the consumer where they are. State of the consumer seems to be able to buy both your highest end products and your more
16:19middling products. Yeah, I think, you know, the consumer right now, it's stopped getting worse, right? The consumer is not in a great spot, but they're not in a terrible spot. The job market's strong. You know, inflation is still a little too challenging. Gas prices a little too challenging. But, you know, we're a staple in many, many cases and we're a treat in other cases. But we've been able to connect with consumers, hold up our business, improve our trends in this country and around the world. And we expect into next year, the first half of 27 is still going to be somewhat of a challenge, a little bit more inflation. But that's OK. That's OK. The back half of 27, we start to see a lot more a lot more opportunities to really get ourselves back to growth.
16:59One of the reasons besides the moving to the exchange that I wanted to have you on was that I've always liked your work, but I did doubt you and Kellogg. I thought that Kellogg were dead brands, that there was nothing there. I didn't do it on air, but you did something rather remarkable at Kellogg. You created a huge amount of wealth. How did you go about doing that when other people didn't see anything? Well, I think the mistake that was made at Kraft Heinz before I arrived in the last several years is this notion that there's a forever brand, that brands can just live on the history of their past. That's not true. But equally, brands that have existed for a long time are not necessarily destined for the dustbin of history. And that's what a lot of
17:40people thought about the brands at Kraft Heinz. And they're simply not. When you look at Heinz, which I've already talked about, but Kraft Mac and Cheese, people said 90 years old, best days are past. New innovation is coming from smaller companies, best days. Well, we innovated. We launched Kraft Power Mac. We launched Kraft Mac and Cheese Restaurant Edition. And the brand is back to growth. And in Canada, we launched a ramen, a cheesy ramen. Under the KD. I saw that. I said, you got to be kidding. We sold out three months worth of stock in a week. We're going to introduce that next year. So you have to innovate. You have to bring new news. You have to bring excitement with your brand. So is high protein jello, is that going to be in a Costco or a
18:26Walmart? Yeah, absolutely. And it tastes delicious. You know, one of the problems with protein is you can't necessarily, it doesn't go with everything. It's hard to match the flavor. Sometimes it's chalky. Sometimes it's off-putting to, you know, put into existing brands. But our R&D team has cracked the code. The chocolate's my favorite. Chocolate jello pudding with protein, I think is going to be a real hit. Okay. So Philadelphia Cream Cheese, a nice brand, always felt that it was under-marketed, underdone. Are you blowing it out? Yeah. So Philadelphia Cream Cheese is a phenomenal brand. We're doing a lot, especially next year. And it's going to be protein-led as well. We've got a big opportunity to drive protein, to steal some share from cottage cheese. And that's going to come
19:10through the Philadelphia name. We're going to do other things in the back half of next year that I think will be equally as exciting. But it's one of our biggest share gainers this year, Philadelphia Cream. Now, people wanted before, you know, the original plan was to split the company in two. What did you see that you knew that wasn't right? I saw a lot that was fixable. I saw a lot of own goals that we had done. And if we spent all of this year separating the business into two separate companies, we would have continued to underinvest in it and we would have invested in the wrong things, which are bankers and lawyers to separate the business, we would have ended up with two suboptimal businesses. By pausing that and by
19:50stopping it and by putting the 700 incremental dollars on top of what we're already spending against the brands, I thought we'd be one bigger, stronger company. The other thing that a lot of businesses like ours have forgotten about is scale can be an advantage, but you have to know what to do with that scale. And so we were going to cut the company in half and become subscale, but instead, we're a $25 billion business that's going to be growing again. That's much more powerful than two businesses that are separated, that are suboptimal, that are not growing. Last question, Steve, is that I did mention about the brands or forever brands. I do think that certain brands I thought had aged out. I thought that both Kraft
20:32and Heinz had aged out. That's clearly not the case. It's not the case. And I'll give you an example. So we we rang the bell of the stock exchange this morning. Before that, we were outside. You know, it was all wonderful. We had the Kool-Aid man outside. We had a crowd of New Yorkers so excited about seeing the Kool-Aid man. Right. They'll buy the T-shirt, but we have to contemporize it. We have to innovate. We have to get people to want to buy the product as well. And we can do that because the brands loved. You sound as fired up as when you did the Kellogg and one of the greatest trades ever. I'm so fired up. It's a great company. It's an important company. It deserves a bright future. And that's what my team and I are bound and determined to deliver,
21:11a bright future for Kraft Heinz. I've got to go all in because I've seen you do it once. I think you're going to do it again. I want to thank Steve K. Lane, CEO of Kraft Heinz. Look, guys, I often point to decks, and they're hard to understand. Is there really anything hard to understand about ketchup and Philly cream cheese? No. Mad Money's back after the break. Thank you, Steve. Thanks, Jim. Coming up, Kramer's wrapping up his anthropic IPO series by identifying what else you need to know beyond the company's financials. Next. At Edward Jones, we believe rich is more than caring about the latest and greatest. It's also taking care of what gives your life meaning. That's why your dedicated financial advisor meets you where you are,
22:06with personalized financial strategies that help protect what matters, so you can preserve your progress while creating a path forward the key to being rich is knowing what counts let's find your rich together edward jones member sipc with my sapphire preferred card we took a trip to a desert oasis earning five times the on Chase Travel, two times the points on all other travel, plus $100 hotel credit. Chase Sapphire Preferred, a card that's preferred for a reason. Cards issued by JPMorgan Chase Bank and a member of FDIC subject to credit approval terms apply. Building a portfolio with Fidelity Basket Portfolios is kind of like making a sandwich. It's as simple as picking your stocks and ETFs,
22:42sort of like your meats and other toppings, and managing it as one big, juicy investment. Mmm, now that's pretty good. Learn more at fidelity.com slash baskets. Investing involves risk, including risk of loss. Fidelity Brokerage Services, LLC. Member NYSC SIPC. Every night this week, I've been spending some time trying to prepare you for next week's historic Anthropic IPO. I've been covering the story from all angles, explaining the stakes and the broad terms of the deal, looking at Anthropic's impressive growth, and examining the company's complicated profitability profile. Tonight, I want to wrap things up for this Know Your IPO series with a quick run-through of all sorts of other considerations for this Anthropic deal, things that aren't reflected in the company's
23:39financials, which is what I've focused on so far. I'm going to start with the pros, and the first thing to call out is the huge cash balance that Anthropic will have after its IPO. I've noted that the company had $132 billion in cash, cash equivalents, and short-term investments at the end of September. And it could add around $100 billion in cash from next week's offering. Now, we do know that they're going to need that cash with some $900 billion in compute commitments on the horizon. That's a great buffer to start. Another thing I like is the fact that 90% of contributions to Anthropix code base are actually being written by Claude at this point. Just in the third quarter, Anthropix saw a 45 times increase in code contributed per engineer from 2024 levels.
24:24That's called productivity. In other words, the product is increasingly making itself and also finding ways to improve itself. For example, using compute more efficiently. This has all sorts of positive benefits. It makes Anthropic more efficient, of course. I don't think it's a coincidence that the company reached profitability at least on an adjusted basis as this has happened. And it allows Anthropic to build new models and products faster. All right, now to the open questions. The first one is about pricing. Anthropic has been cutting prices for many of its models recently, which some have seen as a bearish development and acknowledgement that customers are chafing at their clawed bills
25:00and looking for other options like the open weight models that are so inexpensive. That said, I was encouraged to see that Anthropix revenue growth remained strong in October after many of these price cuts went through. So hey, they may have the swing right. Companies finding other ways to boost revenues as it cuts space prices like adding surcharges. It's actually speed surcharges. And lower prices might be encouraging more overall use of Claude. Still, I'm going to watch the next few months closely to see how these price cuts impact business. Now, the next question. What's the next big use case going to be? I've told you that the extreme growth for Anthropic recently has come from primarily Claude Code.
25:43The company's coding agent gaining traction in the enterprise. And I still think Claude Code has plenty of growth ahead. But for Anthropic's revenue to reach the levels it needs to, and there are some incredible levels that they've got to reach, I want to see more hit products from the company. Anthropic debuted the next major product, Claude Cowork, earlier this year. And they offer some compelling stats about revenue ramping for Cowork much more quickly than it did for Clawed Code. They also rolled out the industry-specific tools. And just this week, Anthropic announced some new products that intend to take on Microsoft Office. Hey, maybe those catch on. But what are the use cases that are going to lead
26:23to the next $100 billion in revenue for Anthropic? It might be cybersecurity, given how good Cloyd is at spotting code vulnerabilities. Anthropic also says that life sciences and robotics could be major end markets. But we'll have to see if those things pan out as well as they expect them to. Finally, for the unknowns, how is Anthropic's safety ethos going to impact the story? Anthropic CEO Dario Almedale loves to remind everyone periodically about how dangerous frontier AI models can be. If he is serious about pacing the frontier, is that negative for revenue growth? But Anthropic has also built its brand around safety. And perhaps that's an asset in a world where customers are both eager to adopt AI for their business and somewhat wary of it.
27:08I don't know, a little contradictory to me, though. That leads directly to my first con. Remember, I did the pros. Here's the cons, which is the question of regulation and even potential liability. On the regulatory front, we've already seen this year that a new precedent has been set where the leading AI labs have to work with the government before releasing new frontier models. And after last year's election, I also wonder whether more Democrats in Washington is a bad thing for the AI industry. Soon we'll look to 2028 and speculate about what a new, less AI-friendly administration really might mean. For now, I just worry that there will be more regulatory constraints for the company, either at the infrastructure level or for its more powerful new models.
27:51As for liabilities, I see here there's some issues. Either that an anthropic model is used for some major cyber attack and that creates legal risk for the company, or as the company's models get increasingly autonomous, they do something they shouldn't, which negatively impacts the customer. Now, I'll add here that I think these regulatory and liability risks are more of a concern for OpenAI than they are for Anthropic, given the latter's safety-first culture. But they are still risks you need to consider for this first major AI IPO. Finally, I want to talk about the company's float. You got to pay attention. This is the biggest issue for me. The float and its lockup expiration schedule. Important details that will go a long way
28:34determining how the stock trades initially. Based on the current numbers, next week's offering represents around 6% of Anthropic shares outstanding. Very similar proportion to what we saw from SpaceX in June. The one difference here is that a tranche of shares from non-founder employees will be unlocked on the first day of trading. That would bring Anthropix float up to around 7% on the first day of trading. But that's still very small. The rest of the shares will be unlocked gradually over the course of the next year via a series of 22 different lockup releases, which start less than a month after the IPO. The concern here is that we will see a big pop initially, as excited investors are competing
29:15for a small number of shares. Then as more shares get unlocked every few weeks, that's going to put downward pressure on Anthropic. The people who are too eager, they get hurt. Basically, I fear that we're going to see a repeat of what happened with SpaceX, where the stock squeezed from its IPO price of $135 to a high of $225 on its third day of trading. Then it came right back down. SpaceX hasn't come close to that initial high since then, but not because the story hasn't gotten better. I don't argue it has. It's just supply and demand. Unfortunately, as I told you last Friday, there's still many more SpaceX shares that have yet to be unlocked. So there you go. There are all kinds of unique considerations for this anthropic deal.
29:52Some are positive, some are negative, and some are legitimate open questions, just things I'm not sure about. I'll have more on the deal next week, of course. But for now, I hope this series that we have run has you feeling more informed about whether to participate in this historic IPO. Here's the bottom line. When the deal terms are finalized next week, I'm going to give you my more formal opinion on whether you should buy Anthropic shares initially or not. For now, I'll just tell you that I'm wary of doing so. Why? Well, because I fear a hot open. But either way, this is the deal to watch. Let's take some calls. Let's go to Mark in Michigan. Mark. Mr. Kramer, it's an honor to speak with you, sir.
30:35Oh, thank you, Mark. What's happening? Well, I've heard you talk a lot about Lambert's search, and I'm wondering if at this point it's a good entry point. I think it is. I think it's come down enough. I think Tim Archer does a terrific job. It is absolutely my favorite. Remember, all the intellectual property when it comes to semiconductors really is from the semiconductor capital equipment, and Lamb's got the best. All right, much more man money ahead, including my exclusive with Moderna. Ben, like I said earlier, I am deeply saddened by the news out of NVIDIA. I'm leaving you with a few more thoughts, to some degree caustic, about the situation. And all your calls are rapid-fire in tonight's edition of the Lightning Round.
31:11So stay with Preem. When you look at the stock of Moderna Go, on August 18th, Moderna was a $63 stock. The next day, it closed above $174. After Moderna and Merck announced that adding their personalized cancer shot to Merck's Keytruda helped keep melanoma from coming back after surgery. Moderna is now up more than 680% for 2026. It did fall 7% today, though. Last week, strong vaccine sales helped Moderna turn a surprise profit, and the company raised its four-year sales forecast. Today, Moderna held this analyst day at the Massachusetts plant that's already making those personalized shots for clinical trials. Earlier today, we caught up with Stephan Van Sell, Moderna's CEO. Take a look. Stephan, welcome to the show on a very big day for you.
32:12Yeah, thank you, Gene, for having me. Well, I've got to tell you, I've been following your progress. And first, I want to just cover the numbers. You're doing so much better. You've got the best flu shot that I can tell. You're doing COVID vaccines. People are telling me they're the ones that don't hurt and don't make you sick. So you've done some traditional things that are really just making you a lot of money, correct? Yeah, I mean, we have really invested in our infectious disease business. Historically, that's where we started, our first product. But we never slept on our laurels. You know, the Mnexpac product, which is the new COVID vaccine, is not only new because of the strain, which of course we have to do
32:49to give you the best protection, but we totally re-engineered the product. It's a new product, like a 2.0 COVID shot. And the dose is one-fifth of a dose of what we had initially. So that's why the side effect is much better. All right. That's the one I've got to get. Now, I just want to, I usually don't do this, but I want to get personal for a second. My daughter had melanoma. Bad. I'm sorry. No, but listen, listen. Your hope, her hope is that your vaccine can make it so she can go back outside and lead a normal life and perhaps have a greater chance of it being cut back. So we're following this thing intensely with everything that I can't read the journal, New England Journal, and understand.
33:34But can you tell us where this is? Because you are the hope for tens of thousands of people. Oh, you're very kind. As you know, we've been working on 10 years on this idea, can you teach the immune system of a patient how to recognize the cancer of a patient and to go eat the cancer? That was the basic idea. And as you I'm sure read, a lot of people thought it was undoable. And it's true that the track record of cancer vaccine behind us was not very good. But we thought with the progress we've made in mRNA, with what we learned with infectious disease vaccine, that our approach had a serious chance. And we took that chance. And to be fair, Merck was a fantastic partner to take that chance and that risk with us.
34:18And what it does basically is when somebody has cancer, you take a biopsy of a tumor, you take a blood draw of a blood, and then you sequence, you next-gen sequence, you read all the letters of the DNA of a cancer and the healthy cell, you send them to the cloud, and you compare letter by letter where is the mutation, where is the cancer, because what we know today is cancer is a disease of DNA, mutation of DNA. And then what we do is we individualize, and I'm just behind me, we basically individualize, we make a product for one human at a time where we put in a cassette of one mRNA molecule, 34 mutation of a cancer of that patient. It's injected in intramuscular every three weeks for nine doors.
35:02And as you know, you saw the data recently, the data is fantastic. I mean, compared to Ketudra, which is an amazing drug in melanoma, nobody has been able since 2018 to do better than Ketudra in melanoma. Several companies tried, there was three phase three that failed, but we were able to show a 42% improvement for patients. And what is even more remarkable, if you look at a phase two study, where we have five years of data, the phase three had only two years of data so far. We'll, of course, share more data as we get the data. We show that the data improves over time. Why? Because the T-cell we created in your body, because of our mRNA, have memory. They stay with you to fight cancer coming back.
35:44Wow. Well, dare I ask when? We're all waiting. We have oncologists that we check with. They want to be sure that things are right before we plunge in. When do you think? So as we've said with our partners at Merck, we are working very, very deliberately to try to get the filing to the FDA before the end of the year. And then we're expecting, assuming a good review by the regulators, that we should be able in 2027 to get the product available to Americans. Well, I'm so glad. I mean, I think if you don't have it or you don't even look, you can go to the Reddit page for the melanomies. You can feel for what people have. But as a parent and the daughter, we are, I never create false hopes for cancer.
36:30Lost my mom for kidney cancer very, very young. I know that those who create false hopes are not good. You have done the opposite. You've not played it high. You have waited and waited. How about other cancers? Are there hopes for it without getting too far ahead and making people feel that there's a magic bullet out there? Sure. And I agree with you, Jim. It's very important. People are suffering with cancer. It's very important for them and their family not to have false hope. So what we're doing beyond melanoma is we have studies ongoing in five different tumor types, including lung cancer. In lung, we're both looking at people that have stage two or three of lung disease, but we're also trying in T-Smeran, that's the name of our medicine, in T-Smeran by itself,
37:18in people that have stage one lung cancer. Because we think given it has a very good safety profile for medicine, it could potentially be used earlier in disease to help people get back to normal life without sometimes the terrible side effect of cancer treatment. So we should get data in kidney cancer pretty soon, either end of this year or next year. Those are event-driven studies when people have recurrence of disease. So of course, we do not control the timing. The one after should be bladder cancer and the one after should be lung. So when we have the data, like we've always done, we will share the data with the community, including the medical community, so we can review the data. Last night, the New England Journal of Medicine, as you know, the most prestigious journal, released the full data set with all the appendix so all the melanoma doctors
38:06can look at the data and understand what the product can do and what the product doesn't do and that's where we are and we're going to keep investing in the science because as you know software is part of the drug because we have to select from hundreds of thousands of mutation 34 that goes in the cassette we think we can learn by going and mining the data in a phase three study and figure out what can we tweak in the software? What was working well in the software? What maybe can we improve so we can potentially even improve that success rate? Again, it's a hypothesis. We need to work and look at the data, but I'm really believing that because of the progress that the medical field is making
38:44and because of the access of AI, when you can look at all those data, think about it, 1,100 patients. That's a lot of data when you look at all the T-cells and the biomarkers and so on. But looking at that with big data, this should be able to get insight. And then to have a discussion with the regulators is a way to upgrade the software. Well, look, congratulations and thank you for helping everyone who has this disease and their family members. We all look forward after that New England Journal of Medicine to start getting lined up and getting our doctors to be aware. Remarkable job. I remember when I met you, you said this could happen and then we got waylaid by COVID, of which you helped solve.
39:27But this is nothing short of remarkable. And I want to thank you for everything you've done, not just for the shareholders, but for the parents and for the patients. Good to see you, Stephan. Thank you so much. Very kind of you. Absolutely. That's Stephan Bencelli, the Moderna CEO. Had a remarkable moment and a great shareholder meeting. Coming up, you've got questions, Kramer's got the answers. Get charged up for a fast-fire lightning round. Next. It is time. It's time for the Light Round. Chris Rizzo. I'm Chris Rizzo. Play the sound. And then the lightning round is over. Are you ready, Skeet? Dad, tell the world I'm Chris Rizzo. Dick in Virginia. Dick. Hi, Jim. Hi, Dick. I'm a club member, and I just got your book in the mail.
40:23Yay. Oh, thank you. Thank you. Let's go to work. Yeah, I sent a stock. It's called Commvault. They're in the data recovery business. And he has both on it. I saw the CEO on Dayside. That's what we call watching TV during the daytime. And he was excellent. I thought he did a very good job. I thought he made a good case for his stock, even though it's up a lot. I think it's a good call by you. Jeffrey in Massachusetts. Jeffrey! What's up, my man? How are you? I'm doing well, Chief. How about you? Good to have you on the show. Not too bad. Excellent. So this stock I've got is down nearly 48% year-to-date. Bright Horizons, BFAM. Fast thoughts? Well, it's a very expensive stock, but that typically means to me the earnings
41:12aren't going to come through. I don't want you to mess around with it. I don't. I'm not done. That's ridiculous. I feel like I've taken like one call. Let's go to Dennis in New York. Dennis. Dennis from Hampton Bays, Jim. Big fan. I'm Mike Zegin, producer from Hampton Bays. I'm going to give a big shout out to her. Regina. I'm sorry, go ahead. Texas Pacific land. You know, I'm not really into the oil stocks, and we made a big deal about that stock when it was the right time, and I'm glad we got off that horse. I'm going to say no to Texas Pacific. And that leads up to the conclusion of the Lightning Round. The Lightning Round is sponsored by Charles Schwab. Coming up, as we wrap up another busy day, Kramer has some final thoughts.
41:59Don't miss his no huddle. Next. Booyah, Jim. Your integrity makes you the booyah saint of Wall Street. Booyah, Jimmy Chill. B-b-b-b-booyah, Jim. Quattruple. That's a lot of booyahs. Look, I'm sad. I did love the guy in the leather jacket. I liked him from the first time I interviewed him in 2010 when the stock was around 30 cents. Accounting for the various splits over the years, called it a Kramer fave. I continued to hear more and more about the company in the years that followed, including from the CEO of Audi North America, who told me that NVIDIA's chips were the secret behind his self-driving technology. At the time, everyone just thought this was a gaming chip company. In 2017, frustrated that people didn't know about the company, I renamed my dog
42:59Everest, changing it to NVIDIA, to call attention to the incredible company that NVIDIA was. That late mutt, half pit bull, half whatever, got a lot of people's attention, including Jensen. He made it bad for NVIDIA to get into headquarters anytime he wanted to. That's kind of Jensen's pixie humor. A couple months later is when I bought the stock from my chapel trust for the first time. The stock was around four bucks. But I only fully realized how special this company was after I spent some time at headquarters and saw amazing things. And not just the employee badges Jensen made for the door. Things like robots being rewarded for picking up jello. Things like a machine drawing a Cezanne seascape in 10 seconds.
43:39When I knew he never painted one, but I asked the machine to do it anyway. The colors were spot on. Shading amazing. I talked about what I say at NVIDIA and what I saw at NVIDIA almost every day for weeks on this show and on Squawk on the Street. You know, at one point my partner David told me he was sick of my touting NVIDIA. I didn't care. I kept doing it. There were so many other things Jensen showed me over the years, especially when I started going to the company's GTC event every year. Each time I went out, I learned some new things. Sometimes they were hysterical. Sometimes they were somber. But they were always brilliant. He introduced me to the neoclouds like Inebius and I ran. He made me realize that his partners like Dell and HPE were obvious buys as the
44:23AI era began. These stocks made fortunes for people. I saw robots make hospital corners, 10 bar, really super stuff. His kids, they were dazzling. But one of the most meaningful things he did was attend a lunch right here at the New York Stock Exchange for CBC investing club members, most of whom had become millionaires because they bought the stock of NVIDIA. We had 70 guests. I wanted a group picture. He said no. He wanted individual selfies with individual people, every one of them, all regular people like you, club members who believed. I saw his graciousness repeatedly. I rejoiced in it. He was always so polite and well-meaning. I introduced my wife to him. He's one of just a few execs in the 22 years I've been doing this that I did that.
45:04She thought he was terrific. He took her seriously, asking plenty of questions right in her eyes, looked at her, showing amazing respect. She was impressed. She thought he was sensational. Over the last couple of years, I saw Jensen all over the place. I thought he was kind of changing. He's having a great time. Why not? Seemingly celebrating and palling around with the president as much as he was working. Although that was just an impression. At one point, I saw him sign a woman's shirt in a place that I thought was inappropriate. Well, maybe that was the new, more successful, cooler, why not Flora Jensen? But he was right back to being serious at the next GTC in San Jose. At all times, I admit I was thrilled to spend
45:40time with him. Just thrilled. You know, I tried not to idolize him for his brilliance. I tried not to put him on a pedestal for spectacular innovations. And I defended everything, including his push to sell previous generation chips to Chinese customers, because I thought he was earnest when he said it was in the best interest of our country to hook Chinese customers on the NVIDIA ecosystem rather than have them build their own. I still do. Never once did I think that there might be other motivations, and I still really hope that's not the case. In the end, unlike so many others, I wanted everything negative said about him stopped. At the very least, give him a chance to explain. Don't take this fine man apart.
46:16He's too important to our nation's future. His body of work was too stellar. We can't afford to lose him if we are going to be the world's AI leader. But it was not too big. The man in the leather jacket let his wife down. He let his kids down. He let his company down. He let his co-workers down. He let his shareholders down. He let his country down. Sadly, he let me, a person who just loved the guy, down. My dog, NVIDIA, died a half dozen years ago. Come to think of it, maybe he was the only one who didn't get let down by the man in the leather jacket. He just didn't live long enough to see it. I like to say that there's always a bull market somewhere, and I promise to try to find it just for you right here on Mad Money.
47:01I'm Jim Cramer. All opinions expressed by Jim Cramer on this podcast are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet, or another medium. You should not treat any opinion expressed by Cramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Cramer's opinions are based upon information he considers reliable, Thank you. we believe rich is about taking care of what gives your life meaning. That's why your financial advisor personalizes your plan to help you preserve your progress and create something that lasts.
47:50Let's find your rich. Edward Jones, member SIPC.

